Linda Rubinstein was named Chief Financial Officer of Nektar Therapeutics, effective May 15, 2026. As of November 6, 2026, Nektar Therapeutics has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 8, 2026, naming 1 appointment (Form 8-K, May 8, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Nektar Therapeutics? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Nektar Therapeutics reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-08. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Nektar Therapeutics files it.
Also on the record for Nektar Therapeutics
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 28, 2026 | Stake report, Schedule 13G/A, by Two Seas Capital LP | 9.8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 7.1% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Two Seas Capital LP | 9.1% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.17% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 7.8% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 9.8% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 15% of the class | 5%+ stakes | Source |
| April 17, 2026 | Stake report, Schedule 13G, by Two Seas Capital LP | 6.8% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 11.1% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by G1 Execution Services, LLC | 4% of the class | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13G, by The Vanguard Group | 5.04% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Nektar Therapeutics now and the warning signs.
Free to see. No signup.
Keep reading
More on Nektar Therapeutics and the records around it.
Nektar Therapeutics elsewhere on the record
- 5%+ stake filings Sep 2026
- Who owns it
Companies that share a holder
- Two Seas Capital LP also filed stake reports on 14 other companies: Calumet, Inc. (Aug 2026), Quantum Corporation (Aug 2026), Sable Offshore Corp. (Aug 2026)
- TCG Crossover GP II, LLC also filed stake reports on 21 other companies: ALX Oncology Holdings Inc. (Aug 2026), First Tracks Biotherapeutics, Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
- G1 Execution Services, LLC also filed stake reports on 45 other companies: AmpliTech Group, Inc. (Aug 2026), Bitdeer Technologies Group (Aug 2026), Compass Diversified Holdings (Aug 2026)
Watch Nektar Therapeutics
Get an email when Nektar Therapeutics files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Nektar Therapeutics?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Nektar Therapeutics: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Nektar Therapeutics covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 22 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-08 | In | Chief Financial Officer | 2026-05-15 | 8-K, 2026-05-08 |
Who leads Nektar Therapeutics, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Linda Rubinstein, appointed, effective 2026-05-15 (filed 2026-05-08).
New leaders reset buying decisions — get the Full Report on Nektar Therapeutics: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Nektar Therapeutics, with the record behind each one.
Find candidates like Chief Financial Officer at Nektar TherapeuticsEvery change, in the filing's words
Appointed: Linda Rubinstein, Chief Financial Officer, effective 2026-05-15
Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.
- On May 7, 2026, the Company announced that Sandra Gardiner will be retiring and stepping down as interim Chief Financial Officer of the Company, effective May 15, 2026.
- Ms. Gardiner, a partner of FLG Partners, LLC, a leading chief financial officer services firm ("FLG"), has served as interim Chief Financial Officer of the Company since April 2023.
- Ms. Gardiner will continue to support the transition as necessary.
- Ms. Rubinstein has over 35 years of operational, financial and capital markets experience in life sciences and investment banking and has been Chief Financial Officer of numerous public and private companies.
- She was most recently the Chief Financial Officer of Adverum Biotechnologies, Inc. from 2022 through its sale to Eli Lilly and Company in 2025.
- As a partner of FLG since 2010, Ms. Rubinstein has served as the permanent or interim Chief Financial Officer of Apexigen, ArmaGen, Diasome, Five Prime, Ingenuity, iPierian, Kezar, PaxVax, Retrotope, Sublimity, True North and Tunitas, among others.
- Prior to FLG, Ms. Rubinstein was the sole principal of RDJ Advisors, providing interim Chief Financial Officer and other consulting services to life science and SaaS companies; held leadership roles at Solexa and ChemoCentryx; and served as Senior Vice President of Lehman Brothers' Global Healthcare Investment Banking Group.
Tools for this story
Each opens in a new tab, filled in for Nektar Therapeutics. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.